Central FGF19 reduces hypothalamic inflammation and improves leptin signaling in obese mice

이 페이지는 아래 학술 논문의 초록(Abstract) 전문을 제공합니다. 원문은 하단 링크에서 확인하세요.

◆ 논문 초록 (Abstract)

Obesity is a chronic metabolic disorder characterized by systemic and hypothalamic inflammation that impairs neuronal signaling and disrupts the fine-tuning of energy balance regulation. Leptin resistance, a hallmark of obesity, arises from this inflammatory state and contributes to increased food intake and reduced energy expenditure (EE). Fibroblast growth factor 19 (FGF19), a gut-derived hormone with beneficial metabolic effects in peripheral tissues, also acts centrally to reduce body weight. However, the mechanisms underlying its hypothalamic action remain unclear. In this study, we investigated whether central administration of FGF19 attenuates hypothalamic inflammation and restores leptin signaling in diet-induced obese (DIO) mice, thereby improving energy homeostasis. DIO mice received FGF19 via intracerebroventricular delivery using a cerebral infusion kit connected to an osmotic pump for 10 days. FGF19 treatment increased EE and reduced food intake in DIO mice, resulting in improved energy balance without changes in locomotor activity. These effects were accompanied by a marked reduction in hypothalamic inflammatory markers and glial activation, including reactive astrocytes. Notably, FGF19 restored hypothalamic leptin-induced Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) phosphorylation and normalized expression of anorexigenic neuropeptides. Our findings position FGF19 as a central regulator of leptin sensitivity and hypothalamic inflammation, highlighting its therapeutic potential for obesity through modulation of appetite and EE.

◆ 원문 정보
저자: Zangerolamo L, Carvalho M, Bem KCP, Boschero AC, Velloso LA et al.
저널: Eur J Pharmacol
연도: 2026
DOI: 10.1016/j.ejphar.2026.178643

PubMed 원문 보기 →   DOI 바로가기 →

🔗 이 논문을 인용한 글

• 배고프지 않은데 살이 빠진다? 렙틴 호르몬을 깨우는 식습관의 비밀
• 먹어도 배고픈 이유? 렙틴 저항성이 식욕을 조종하는 방법